Gsk (GSK) Consolidated Net Income (2009 - 2026)

Gsk (GSK) has 18 years of Consolidated Net Income data on file, last reported at $3.5 billion in Q3 2026.

• For the quarter ending Q3 2026, Consolidated Net Income changed N/A year-over-year to $3.5 billion; the trailing twelve-month figure through Sep 2026 stood at $13.8 billion (changed N/A YoY), and the FY2025 full-year result was $11.3 billion, up 121.3% from the prior year.
• Consolidated Net Income was $3.5 billion for Q3 2026 at Gsk, up from $208.0 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $16.9 billion in Q4 2022 to a low of $81.9 million in Q3 2024.
• A 5-year average of $4.3 billion and a median of $3.1 billion in 2025 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income slumped 96.84% in 2024 and jumped 4462.94% in 2025, its largest moves.
• Gsk's Consolidated Net Income stood at $16.9 billion in 2022, then plunged by 65.82% to $5.8 billion in 2023, then decreased by 24.92% to $4.3 billion in 2024, then jumped by 56.77% to $6.8 billion in 2025, then plunged by 48.53% to $3.5 billion in 2026.
• Per Business Quant data, the three most recent Consolidated Net Income figures were $3.5 billion in Q3 2026, $208.0 million in Q2 2026, and $3.3 billion in Q1 2026.